Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
1.320
+0.020 (1.54%)
At close: Jun 6, 2025, 4:00 PM
1.400
+0.080 (6.05%)
After-hours: Jun 6, 2025, 7:59 PM EDT
Galectin Therapeutics Employees
Galectin Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 1 or 7.14% compared to the previous year.
Employees
15
Change (1Y)
1
Growth (1Y)
7.14%
Revenue / Employee
n/a
Profits / Employee
-$3,020,533
Market Cap
83.54M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GALT News
- 26 days ago - Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - GlobeNewsWire
- 2 months ago - Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - GlobeNewsWire
- 6 months ago - Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? - Benzinga
- 6 months ago - Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH - GlobeNewsWire
- 7 months ago - Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire
- 7 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - GlobeNewsWire
- 8 months ago - Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire